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Studies of changes in the virus and host cell upon progression from human papillomavirus (HPV) episomal infection to integration are
critical to understanding HPV-related malignant transformation. However, there exist only a few in vitro models of both productive HPV
infection and neoplastic progression on the same host background. We recently described a unique foreskin keratinocyte cell line (ERIN 59)
that contains HPV 59 (a close relative of HPV 18). Early passages of ERIN 59 cells (passages 9–13) contained approximately 50 copies of
episomes/cell, were feeder cell-dependent, and could be induced to differentiate and produce infectious virus in a simple culture system. We
now report that late passage cells (passages greater than 50) were morphologically different from early passage cells, were feeder cell
independent, and did not differentiate or produce virus. These late passage cells contained HPV in an integrated form. An integration-derived
oncogene transcript was expressed in late passage cells. The E2 open reading frame was interrupted in this transcript at nucleotide 3351.
Despite a lower viral genome copy number in late passage ERIN 59 cells, expression of E6/E7 oncogene transcripts was similar to early
passage cells. We conclude that ERIN 59 cells are a valuable cell line representing a model of progression from HPV 59 episomal infection
and virus production to HPV 59 integration and associated oncogenic transformation on the same host background.
D 2005 Elsevier Inc. All rights reserved.Keywords: Human papillomavirus; Keratinocyte; ERIN 59Introduction
Infection of the genital epithelium in both females and males
with certain types of human papillomavirus (HPV) is associated
with an increased risk of dysplasia and invasive malignancy
(Koutsky, 1997; Schiffman and Brinton, 1995; Schiffman and
Burk, 1997). These dysplastic lesions sometimes persist and
progress to invasive cancers. In low-grade pre-neoplastic lesions
the HPV genome generally exists in an episomal form, and the
host cell can differentiate permitting production of infectious0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.02.026
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E-mail address: darbrow@iupui.edu (D.R. Brown).virus (Badaracco et al., 2002; Das et al., 1992; Evans et al.,
2002; Gross and Pfister, 2004; Hernadi et al., 2004; Hopman et
al., 2004; Hudelist et al., 2004; Lizard et al., 1998). Conversely,
in high-grade lesions and cancers, the HPV genome usually is
integrated into the host chromosomal DNA, the host cell
differentiates aberrantly, and virus is not produced (Das et al.,
1992; Hopman et al., 2004; Hudelist et al., 2004).
Several in vitro models developed from HPV immortal-
ized keratinocytes have proven useful in studies of viral
pathogenesis. Cell lines containing integrated viral sequen-
ces such as HeLa, CaSki, SiHa, and others were developed
from cervical carcinomas and have proven valuable in
studying the HPV-induced neoplastic phenotype (El Awady
et al., 1987; Lazo, 1987; Stupar, 1989).005) 11–25
H. Spartz et al. / Virology 336 (2005) 11–2512In contrast, several cell lines derived from HPV-infected
clinical specimens contain episomal HPV and have been
valuable for studying other aspects of the viral life cycle. For
example, CIN-612 cervical keratinocytes contain episomal
HPV 31b (DeGeest et al., 1993; Hummel et al., 1992; Ozbun,
2002; Ozbun and Meyers, 1997). The W12 cell line (also
cervical keratinocytes) initially contained episomal HPV 16
in early passages but was found to have integrated HPV 16
sequences after in vitro passages (Alazawi et al., 2002; Flores
and Lambert, 1997; Jeon et al., 1995; Stanley et al., 1989;
Sterling et al., 1990) The CIN-612 and W12 cells require raft
culturing systems for virus production. HPV 16 and HPV 31b
have been maintained as episomes in these rafts, providing an
additional method for analysis of the HPV life cycle. The UT-
DEC-1 vaginal keratinocyte cell line contains episomal HPVFig. 1. Alignment of E2 DNA sequences from ERIN59 cells (top sequence), the p
HPV 18 E2 DNA sequence (bottom sequence). Nucleotides are indicated by singl
shown on the left side of the figure. Bold lettering indicates nucleotides matching w
nucleotides for all three sequences. The DNA sequence between E2 position 24
position 377, equivalent to HPV 59 position 3118 (arrow over the position), corr33 in early passage cells and integrated viral DNA in late
passage cells (Auvinen et al., 1998; Hietanen et al., 1992;
Peitsaro et al., 2002).
These cell lines have proven valuable for analyzing the
differences in both virus and host between episomal and
integrated viral forms. It is important to establish additional
in vitro models to assess whether observations made in
W12, CIN 612, and UT-DEC-1 are also seen for other high-
risk HPV types, and in other genital keratinocytes of
different genetic backgrounds.
We recently developed ERIN 59 cells, a foreskin
keratinocyte cell line containing HPV 59, an oncogenic type
related to HPV 18 and HPV 45 (Bryan et al., 2000; Lehr et al.,
2003; Rho et al., 1994, 1996). Our prior studies indicated that
ERIN 59 cells initially contained approximately 50 copies ofublished HPV 59 E2 DNA sequence (middle sequence), and the published
e letter designation, and the number of the nucleotide within the E2 ORF is
ith the sequence from ERIN59 cells. The star symbols (*) indicate matching
1, equivalent to HPV 59 position 2970 (arrow over the position), and E2
espond to the putative inversion error in the published HPV 59 sequence.
Fig. 1 (continued).
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entiate and produce infectious virus in a simple culture
system that does not require rafts or engraftment into or onto
mice (Lehr et al., 2003). During passage in vitro, we found
evidence that HPV 59 sequences had integrated into cellular
DNA. Thus, ERIN 59 cells could provide a unique model to
study HPV 59 in both episomal and integrated forms on the
same host background. Our studies focus on phenotypic and
molecular differences in the virus and the host cell between
HPV 59 in an episomal or integrated state.Results
DNA sequence analysis of HPV 59 in ERIN 59 cells
DNA extracted from ERIN 59 cells was used in a PCR/
reverse blot strip assay, which amplifies a portion of the L1open reading frame (ORF). The PCR/reverse blot strip assay
indicated the presence of HPV 59 DNA in ERIN 59 cells
harvested at early and late passages (data not shown).
Published HPV 59 sequences have indicated that the E2
ORF contained an inverted portion in relationship to other
HPV types between nucleotide (nt) positions 2970 through
3118 (Rho et al., 1994). It was suggested that this inversion
could inactivate the transcriptional repressive activities of
E2 in HPV 59.
In an attempt to verify this distinctive inversion, DNA
was isolated from early passage ERIN 59 cells and the E2
gene was subsequently cloned and sequenced. The E2
DNA sequence of our HPV 59 isolate was very similar to
the published HPV 59 sequence except in the region from
nt 2970 through nt 3118, the region of the putative
inversion (Fig. 1). The assigned GenBank accession
number for the HPV 59 E2 sequence from ERIN 59 cells
is AY923027.
Fig. 1 (continued).
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from our isolate was also similar to the published HPV 59
sequence except in the region corresponding to the aminoFig. 2. Alignment of E2 proteins based on the DNA sequence from ERIN59 cells
(middle sequence), and the E2 protein based on published HPV 18 DNA sequence
and the number of the amino acid within the E2 protein is shown on the left side of
from ERIN59 cells. Star symbols (*) indicate matching amino acids for all three s
over the residue) and the aspartic acid (D) at position 126 (arrow over the residue) cacids encoded by nt 2970 through nt 3118 (Fig. 2). In
contrast, the E2 DNA and protein sequences of our HPV 59
isolate shared a high degree of homology with those of HPV(top sequence), the protein based on the published HPV 59 DNA sequence
(bottom sequence). Amino acids are indicated by single letter designation,
the figure. Bold lettering indicates amino acids matching with the sequence
equences. The sequence between the methionine (M) at position 81 (arrow
orrespond to the putative inversion error in the published HPV 59 sequence.
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These data suggest that, in contrast to the published HPV 59
E2 sequence (Rho et al., 1994), the HPV present in ERIN 59
cells does not contain an inversion within E2.
Morphology, growth requirements, and tumorigenicity of
late passage ERIN 59 cells
ERIN 59 cells were originally derived from an HPV
59-infected foreskin xenograft grown in an athymic
mouse (Lehr et al., 2003). Initially, early passage ERIN
59 cells were grown in complete F medium and required
the presence of mitomycin-treated J2 fibroblasts (Flores et
al., 1999). Compared to primary human keratinocytes
(PHKs) (Fig. 3, panel A), early passage ERIN 59 cells
were smaller and pleomorphic (Fig. 3, panel B). After
approximately 50 passages, ERIN 59 cells could be
grown in complete F medium without fibroblasts, had
larger and atypical nuclei, with numerous multinucleate
cells and mitotic figures (Fig. 3, panel C). Attempts to
grow early passage cells without fibroblasts were
unsuccessful.
Soft agar colony formation assays were performed to
assess the anchorage-independent growth capacity of early
passage ERIN 59 cells (passage 13) and late passage ERIN
59 cells (passage 137) (Fig. 4). PHKs did not form colonies
in soft agar (Fig. 4, panels A and D). Early passage ERIN 59
cells formed an average of 0.7 colonies per high power field
(Fig. 4, panels B and D). In contrast, late passage ERIN 59
cells formed an average of 14.0 colonies per high power
field (Fig. 4, panels C and D).
Both early passage ERIN 59 cells (passage 12) and late
passage ERIN 59 cells (passage 63 and passage 95) failed to
develop tumors in athymic mice after subcutaneous injec-
tion. Four injection sites were observed from each passage
of cells analyzed. In contrast, HeLa cells generated robust
subcutaneous tumors under the same conditions (data not
shown).
Late passage ERIN 59 cells contain integrated HPV 59,
disrupted within the E2 ORF
The tyramide-amplified DNA in situ hybridization
method provides evidence regarding the physical state
of HPV viral DNA (Cooper et al., 1991; Evans and
Cooper, 2004; Evans et al., 2002; Kerstens et al., 1995;
Sano et al., 1998). Cells containing episomal DNA
display a diffuse, whole nuclear signal while cells with
integrated viral DNA show punctate signals within nuclei.
Therefore, the physical state of HPV 59 in late passage
ERIN 59 cells was analyzed using tyramide-amplified
DNA in situ hybridization. As a negative control, an
assay of an uninfected foreskin xenograft grown in an
athymic mouse was performed, yielding no signal (Fig. 5,
panels A and B). As a positive control for episomal HPV
59 infection, an assay of an HPV 59-infected foreskinxenograft was performed. A diffuse, whole nuclear signal
was detected in the most differentiated cells of the
infected xenograft (Fig. 5, panels C and D). Early
passage ERIN 59 cells were previously shown to contain
episomal HPV 59 (Lehr et al., 2003). Analysis of early
passage ERIN 59 cells (passage 12), grown under
differentiation inducing conditions, revealed a diffuse,
whole nuclear signal consistent with episomal DNA (Fig.
5, panels E and F). In contrast, analysis of late passage
ERIN 59 cells grown under similar conditions revealed
punctate signals consistent with integrated HPV 59 (Fig.
5, panels G and H). The greater intensity of the staining
seen in panels D and F compared to panel H may reflect
the amplification of HPV 59 DNA by vegetative
replication in these cells following growth under differ-
entiation-inducing conditions. Hematoxylin- and eosin-
stained sections are shown as a reference for size and
density of nuclei (Fig. 5, panels A, C, E, and G).
As indicated above, early passage ERIN 59 cells
contain approximately 50 copies of episomal HPV 59 per
cell (Lehr et al., 2003). To further determine the form
and copy number of the viral genome in late passage
(passage 142) ERIN 59 cells, Southern blot analysis was
performed. The HPV 59 radiolabeled DNA hybridized
with high molecular weight uncut late passage ERIN 59
DNA (Fig. 6, lane 6), consistent with integrated or
multimeric viral DNA. To distinguish between these two
alternatives, ERIN 59 DNA was cut with BamHI, which
cleaves HPV 59 once. If the genome is multimeric and/or
episomal, BamHI digestion should yield HPV DNA
migrating at the position of full-length HPV 59 8 kb
DNA. Instead, two bands were seen, at approximately 18
and 6 kb, consistent with an integrated viral form at a
single locus (Fig. 6, lane 4). The absence of an 8-kb
HPV band in the BamHI digested DNA further suggests
that the integrant is not present in a head-to-tail multi-
meric form. To substantiate that the viral genome was
integrated at a single site, ERIN59 DNA was cleaved
with HindIII, which does not cleave HPV 59 DNA. The
HPV 59 whole genomic probe hybridized with HindIII-
digested DNA as a single band of approximately 19 kb
(Fig. 6, lane 5). Incomplete HindIII digestion was
responsible for the diffuse signal at approximately 23
kb, as a repeat of the Southern blot with longer HindIII
digestion produced only a single band at 19 kb (data not
shown). Thus, only a single integration site was detected.
Copy number controls indicated that the viral copy
number in the late passage ERIN 59 cells was
approximately one copy per cell (Fig. 6, lanes 1–3).
Lastly, limiting cycle PCR was performed on DNA
from early and late passage ERIN 59 cells. In early
passage cells, amplimers from viral genes E6, E7, E1,
L1, and E2 were visualized after 20 cycles of amplifi-
cation (Fig. 7, rows labeled ‘‘E’’). In contrast, amplimers
from viral genes E6, E7, E1, and L1 were visualized
only after 26 cycles of amplification using equivalent
Fig. 3. Phase contrast micrographs of cells grown as monolayers. (A) PHKs; (B) early passage (passage 8) ERIN 59 cells. Arrow indicates J2 feeder fibroblasts.
(C) Late passage (passage 98) ERIN 59 cells. Arrowhead indicates a mitotic figure. Asterisk indicates a multinucleate cell. Original magnification: 200.
H. Spartz et al. / Virology 336 (2005) 11–2516quantities of whole genomic DNA from late passage
ERIN 59 cells (Fig. 7, rows labeled ‘‘L’’). In addition,
although abundant E2 amplimers were obtained from
early passage ERIN 59 cellular DNA, E2 could not beFig. 4. Analysis of soft agar colonies. (A, B, and C) Phase contrast micrographs o
passage ERIN 59 cells (C). Original magnification: 200. (D) Graph indicating th
and late passage ERIN 59 cells. Standard deviations reflect the differences betweamplified by PCR from late passage ERIN 59 cell DNA,
even after 35 cycles (data not shown). Failure to amplify
E2 sequences is consistent with disruption of the E2
ORF upon integration.f soft agar colonies of PHKs (A), early passage ERIN 59 cells (B), and late
e average number of soft agar colonies per high power field (hpf) for early
en three experimental replicates.
Fig. 5. Histologic and DNA in situ hybridization analysis to detect HPV 59
sequences in foreskin xenografts and in cells grown in complete F medium
with 2 mM calcium chloride to induce differentiation. Hematoxylin and
eosin (H&E) section (A) and DNA in situ analysis (B) of uninfected
foreskin xenograft. H&E section (C) and DNA in situ analysis (D) of HPV
59-infected foreskin xenograft. H&E section (E) and DNA in situ analysis
(F) of early passage ERIN 59 cells. H&E section (G) and DNA in situ
analysis (H) of late passage ERIN 59 cells. Arrows in panels A and C
indicate the basal cell layer in the foreskin xenografts. Original
magnification: 400.
Fig. 6. Southern blot analysis of late passage (passage 142) ERIN 59 cells.
Copy number controls, as indicated in the text, are shown in lanes 1
(approximately 9.6 copies per cell), 2 (approximately 1.9 copies per cell),
and 3 (approximately 1.0 copy per cell). DNA from late passage ERIN 59
cells was digested with BamHI (lane 4), HindIII (lane 5), or no enzyme
(lane 6). Molecular markers (in kb) are indicated on the left side of the
figure.
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integration-derived HPV oncogene-containing transcript
An integration-derived HPV 59 oncogene transcript
was detected in late passage ERIN 59 cells using analysis
of papillomavirus oncogene transcripts (APOT) (Klaes et
al., 1999). This transcript encodes the complete E6 and
E7 ORFs, followed by 16 nucleotides (nts) of E1 spliced
to the 3V end of the E1 gene at base pair position 2695.
The splice is upstream of the start of E2 at nt 2736. The
E2 gene is intact through nt 3351 of HPV 59, where the
viral sequence abruptly ends and is followed by 22 nts of
presumably cellular encoded transcript just prior to the
polyA+ tail (Fig. 8). This was the only transcript
recovered in multiple independent APOT analyses and is
therefore likely to be the predominant oncogene transcript.
No E6 splice variants were recovered. The HPV 59sequence at nt 3351 does not resemble a consensus splice
donor site. Therefore, it is unlikely that the switch from
HPV 59 E2 sequence to cellular sequence represents a
splice donor/acceptor site. A single-base polyadenylation
signal variant, AATAGA, was located 19 base pairs
upstream of the polyadenylation site within the cellular
encoded sequence. Therefore, it is likely that the E2 gene
is disrupted by integration at nt 3351 and the integration-
derived transcript reflects the native junction between
virus and host DNA.
As indicated above, the transcript contained nt 2736
through nt 3351 of the E2 ORF. The complementary E2
sequence of the transcript matched that of the E2 sequence
of our HPV 59 isolate, including the region from nt 2970
through nt 3118, (the region of the putative inversion). The
viral genes E6 and E7 were also sequenced from the
integration-derived transcript and showed high homology to
published HPV 59 sequences (data not shown).
Because the transcript contained only 22 nts of cellular
encoded message, we were unable to determine the cellular
integration loci based on the APOT analysis as a BLAST
search retrieved numerous regions within the human
genome having homology to this sequence. We are therefore
currently employing other methods to determine the precise
integration locus. These future studies will also allow
confirmation that the viral/cellular junction in this transcript
is not due to splicing.
Fig. 7. Limiting cycle PCR to amplify HPV 59 genes. Rows labeled ‘‘E’’: PCR using DNA from early passage (passage 13) ERIN 59 cells. Rows labeled ‘‘L’’:
PCR using DNA from late passage (passage 63) ERIN 59 cells. The primer sets used in each PCR are indicated at the top of each set of rows. GAPDH was
used as an internal control for balanced DNA content. Cycle numbers are indicated at the bottom of the figure (see text for explanation).
H. Spartz et al. / Virology 336 (2005) 11–2518To compare the relative abundance of oncogene-
encoding transcripts in early and late passage ERIN 59
cells, limiting cycle RT-PCR was performed using RNA
from these cells (Fig. 9). E6/E7-encoding transcripts were
expressed at similar levels in cells from both passages,
despite a higher DNA copy number in early passage
cells. As expected, transcripts potentially encoding the
complete E2 ORF were not detected by RT-PCR in late
passage ERIN 59 cells.
Late passage ERIN 59 cells have a decreased capacity to
differentiate
Some degree of differentiation is necessary for HPV
virus production. Yet failure of differentiation or mark-
edly aberrant differentiation is a characteristic of tumor
cells. Therefore, studies were conducted to characterize
the differentiation capacity of early and late passage
ERIN 59 cells. To detect cellular transcripts encoding
involucrin (a cornified cell envelope protein expressed inFig. 8. Diagram representing E6 and E7 oncogene encoding viral–cellular fusi
sequence indicate the positions of splice donor/acceptor nucleotides. The HPV 59
nt 542 through nt 864. HPV 59 E2 spans from nt 2736 through nt 3848. E2 is inter
non-HPV, presumably cellular, encoded transcript immediately preceding the polydifferentiated keratinocytes), limiting cycle RT-PCR was
performed using RNA from PHKs (Fig. 10, rows labeled
‘‘P’’), and from early passage ERIN 59 cells (Fig. 10,
rows labeled ‘‘E’’) and late passage ERIN 59 cells (Fig.
10, rows labeled ‘‘L’’) following 7 days of stimulation
with 2 mM calcium chloride to induce differentiation. All
differentiation studies were conducted on cells adherent
to plastic tissue culture flasks. Calcium chloride was
added to the regular cell culture medium. Upon calcium-
induced differentiation, transcripts potentially encoding
involucrin were detected in early passage ERIN 59 cells
at levels comparable to PHKs, while late passage ERIN
59 cells expressed lower levels of involucrin transcripts
(Fig. 10, middle group of rows). Early passage ERIN 59
cells also produced abundant levels of transcripts encod-
ing the L1 major capsid protein upon calcium-induced
differentiation (Fig. 10, right group of rows). Late
passage ERIN 59 cells produced fewer L1 transcripts
than early passage ERIN 59 cells under the same
conditions.on transcript detected in late passage ERIN 59 cells. Numbers under the
E6 ORF spans from nt 55 through nt 537. The HPV 59 E7 ORF spans from
rupted in this transcript at nt 3351, and is immediately followed by 22 nts of
A+ tail.
Fig. 9. Limiting cycle RT-PCR to detect HPV 59 transcripts. Rows labeled ‘‘E’’: RT-PCR using RNA from early passage ERIN 59 cells (passage 9). Rows
labeled ‘‘L’’: RT-PCR using RNA from late passage ERIN 59 cells (passage 73). The primer sets used in each RT-PCR are indicated at the top of each set of
rows. GAPDH was used as an internal control for balanced DNA content. Cycle numbers are indicated at the bottom of the figure (see text for explanation).
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cells, stimulated to differentiate with calcium chloride, was
also performed to look for evidence of differentiation (Fig.
11). PHKs and early passage ERIN 59 cells grown as
submerged cultures showed a limited degree of stratification
(three to four cells in thickness), while late passage ERIN 59
cells were only one to two cells thick. Immunohistochemical
analysis was performed to detect involucrin and L1 proteins.
Involucrin was detected in abundance in PHKs and early
passage ERIN 59 cells, but not in late passage ERIN 59
cells. The L1 major capsid protein was detected in early
passage ERIN 59 cells as a nuclear signal (Fig. 11, panel H),
but was not detected in late passage ERIN 59 cells (Fig. 11,
panel I). Analysis of cells with preimmune rabbit serum
yielded no appreciable signals (data not shown).Discussion
ERIN 59 cells are immortalized human foreskin kerati-
nocytes derived from an HPV 59-infected foreskin xeno-
graft grown in an athymic mouse (Lehr et al., 2003). HPV
59 is a high-risk type closely related to HPV 18, sharing a
71% overall sequence homology (Rho et al., 1994, 1996).
The ERIN 59 cell line provides a valuable model to study
the progression of HPV-induced disease from episomal viral
infection, in which infectious virions can be produced to
integration and associated neoplastic changes.
The previously published sequence of HPV 59 indicated
a large inversion within the E2 ORF. It has been suggested
that this inversion may obliterate the transcriptional repres-
sive function of E2 in HPV 59 infection. However, no
portion of the E2 ORF was inverted in our HPV 59 isolateFig. 10. Limiting cycle RT-PCR for detection of differentiation-specific transcrip
calcium chloride. Rows labeled ‘‘P’’: PHKs. Rows labeled ‘‘E’’: early passage E
(passage 100). GAPDH was used as an internal control for balanced RNA levels
indicated at the bottom of the figure.compared to HPV 18. Rather, E2 was closely homologous
with the HPV 18 E2 sequence at the DNA and protein level.
It is possible that the published HPV 59 isolate may in fact
contain this inversion within E2. Another possible explan-
ation, suggested by the authors of the published sequence, is
that an error occurred during the alignment process (Rho et
al., 1994). Regardless of the reason for the disparity, our
HPV 59 isolate is homologous to HPV 18 throughout the E2
ORF at the nucleotide and amino acid level. These results
demonstrate an even closer overall homology between HPV
59 and HPV 18 than was previously known. We concluded
that our HPV 59 isolate contained no inversion in the E2
region.
The results also suggest that the transcriptional repressive
function ascribed to the E2 gene in other high-risk HPV
types is conserved in HPV 59 E2 (Bernard et al., 1989;
Demeret et al., 1997; Dowhanick et al., 1995; McBride and
Howley, 1991; Nishimura et al., 2000; Thierry and Howley,
1991). It is worth noting that E2 did not repress HPV
transcription of E6 and E7 in W12 cells containing episomal
HPV 16 (Bechtold et al., 2003). However, in S12 cells, an
isolate of W12 cells containing integrated HPV 16, ectopic
expression of E2 elicited strong repression of E6 and E7
transcription (Bechtold et al., 2003).
Disruption within the E2 ORF is frequently observed in
cervical malignancies, and the disruption of the E2-depend-
ent negative feedback controlling E6/E7 transcription is
considered a selective event in tumor development and
progression (zur Hausen, 1991; Romanczuk and Howley,
1992). In late passage ERIN 59 cells, E2 was found to be
disrupted at the DNA level. Transcriptional analyses
revealed that an oncogene-containing viral transcript also
contained E2 sequences, truncated at base pair positionts using RNA from cells grown in complete F medium containing 2 mM
RIN 59 cells (passage 12). Rows labeled ‘‘L’’: late passage ERIN 59 cells
. Primer sets are indicated at the top of each set of rows. Cycle number is
Fig. 11. Histology and immunohistochemical analysis of PHKs (A, D, and G), early passage (passage 12) ERIN 59 cells (B, E, and H) and late passage
(passage 52) ERIN 59 cells (C, F, and I) grown submerged in complete F medium containing 2 mM calcium chloride. Histology is indicated in hematoxylin and
eosin-stained sections (A, B, and C). Immunohistochemical analysis to detect involucrin (D, E, and F) and the L1 major capsid protein (G, H, and I). The arrow
in panel H indicates the nucleus of a cell that stained positive for L1 protein in early passage ERIN59 cells. Original magnification: 400.
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passage ERIN 59 cells, an E2 protein encoded from this
message would be missing the DNA binding portion, thus
abrogating a transcriptional repressive function (Dowhanick
et al., 1995; Gillitzer et al., 2000; McBride and Howley,
1991).
As expected in the case of abrogated E2 function, the
production of E6 and E7 transcripts was high in late passage
cells in spite of a lower viral copy number compared to early
passage cells. This has been previously observed for HPV
16-immortalized cervical keratinocytes, in which a selective
growth advantage was noted for clones containing inte-
grated HPV sequences (Jeon et al., 1995). In spite of lower
HPV copy number in these clones, the expression of E7
exceeded that in clones with episomal HPV 16, most likely
a result of loss of E2-mediated repression of E6/E7
transcription in the clones with integrated HPV. In the case
of ERIN59 cells, this suggests that the loss of E2 in late
passage cells has resulted in a lack of E2-mediated
transcriptional repression and provides additional evidence
that HPV 59 E2 acts as a transcriptional repressor to down-
regulate transcription of E6 and E7 oncogenes.
Low-grade HPV-associated dysplastic lesions and cell
lines derived from these lesions retain some degree of
differentiation and the potential to produce infectious virus
(De Geest et al., 1993; Fichorova et al., 1997; Sterling et al.,
1993). In contrast, high-grade lesions and carcinomas
differentiate poorly and are devoid of virus production.
Poor or absent differentiation is a feature of cervical cancers
(Robboy et al., 2002). While early passage ERIN 59 cells
showed a degree of differentiation in culture when
stimulated with calcium, late passage ERIN 59 cells showed
much less differentiation under the same conditions. Thus,
this progression towards failure to differentiate was re-
capitulated in ERIN 59 cells, suggesting that these cells
represent a useful model of HPV 59-induced neoplasia.Anchorage-independent growth is generally accepted as
an in vitro property of neoplastic cells. Late passage ERIN
59 cells had an increased capacity for anchorage-independ-
ent growth compared to early passage ERIN 59 cells. This
progression towards increased capacity for anchorage-
independent growth further suggests that these cells
represent a useful model of HPV 59-induced neoplasia.
Consistent with these observations, late passage ERIN 59
cells exhibited some phenotypic traits associated with neo-
plasia that were not evident in early passage cells. Such traits
included the ability to grow in the absence of fibroblast
feeders, enhanced nuclear atypia, increased capacity for
anchorage-independent growth, and reduced differentiation
capacity. Primary cells generally require exogenous growth
factors for continuous proliferation (Herlyn et al., 1990).
However, cell lines developed from transformed cells or
carcinomas as diverse as tracheal epithelium, bladder, colon,
ovary, and cervix are able to proliferate after a short
adaptation period in medium depleted of growth factors.
Additionally, with time in culture, cells show a reduction of
their growth requirements (Aaronson, 1991; Herlyn et al.,
1990). Thus, the process of in vitro passaging could, in part,
account for the decreased growth requirements and increased
nuclear atypia in late passage ERIN 59 cells, which prompted
us to begin these studies. This is even more probable when
taking into account the continuous exposure to high levels of
E6 and E7 oncogenes throughout in vitro passaging.
A second contributing factor to the more malignant
phenotype observed in late passage ERIN 59 cells is the
physical state of the HPV 59 genome. Premalignant lesions
of the cervix typically contain HPV predominantly in an
episomal form, while cervical carcinomas usually contain
integrated HPV sequences (Badaracco et al., 2002; Das et
al., 1992; Evans et al., 2002; Gross and Pfister, 2004;
Hernadi et al., 2004; Hopman et al., 2004; Hudelist et al.,
2004; Lizard et al., 1998). Therefore, it follows that the
H. Spartz et al. / Virology 336 (2005) 11–25 21phenotype of cells with integrated HPV DNAwould exhibit
a more neoplastic phenotype than cells with episomal HPV
DNA. Integration of HPV sequences into the human
genome has been shown to enhance the stability of E6/
E7-encoding transcripts, providing a potential means of
optimizing the effects of these oncogenes on cellular growth
(Jeon and Lambert, 1995). HPV 59 is a close relative of
HPV 18. It has been suggested that HPV 18 may possess an
enhanced ability to integrate into the host genome at an
early point in infection compared to HPV 16 (Badaracco
et al., 2002).
It has recently been shown that the integration of
high-risk HPV is associated with numerous changes in
cellular gene expression (Alazawi et al., 2002) and with
acquisition of high-level chromosomal instability (Pett et
al., 2004). Thus, the integrated state of the viral genome
in late passage ERIN 59 cells might contribute to an
increasingly unstable genome allowing the acquisition of
chromosomal abnormalities associated with neoplastic
progression. Alternatively, the presence of integrated viral
DNA may simply reflect the increase in genomic
instability induced by prolonged exposure to E6 and E7.
While HPV infection and neoplastic progression has
been most widely studied in cervical cancer, HPV also
plays an important role in carcinogenesis of the vagina
(Barzon et al., 2002; Daling et al., 2002; Logani et al.,
2003; van Beurden et al., 1998) and penis (Bezerra et al.,
2001; Dillner et al., 2000; Gross and Pfister, 2004). As
indicated above, ERIN 59 cells were derived from
foreskin keratinocytes. In spite of their different cellular
origin, ERIN 59 cells share many common phenotypic
features of neoplasia with W12 and UT-DEC-1 cells,
derived from cervical and vaginal keratinocytes, respec-
tively. Notably, all three cell lines contained episomal
HPV at early passage and were superseded by cells
containing integrated HPV during passage in vitro.
For all three of these cell lines, early passage cells
provide a model for the study of episomal infection and
the viral life cycle. Virus particles have been produced
from early passages of both the W12 cell line and ERIN
59 cell line (Flores and Lambert, 1997; Lehr et al.,
2003). These cell lines and UT-DEC-1 cells have
exhibited progressive changes towards a malignant
phenotype in later passages (Auvinen et al., 1998; Pett
et al., 2004). Thus, these cell lines each serve as
important models of HPV-induced neoplastic progression
in different genital keratinocytes.
Comparisons among these cell lines will help elucidate
common features of HPV-induced neoplastic progression
at different sites susceptible to HPV infection and disease.
Contrasting observations between these cell lines might
also shed light on how different HPV types affect
progression of HPV-induced neoplasia. Also, it is
important to examine differences between HPV infection
involving various host genetic backgrounds, and different
anatomical locations of infection.Methods
Cell culture
PHKs derived from foreskin were grown in Epilife
growth media (Cascade Biologics, Inc. Portland, OR). Early
passage ERIN 59 cells were plated onto J2 feeder fibroblasts
(treated with mitomycin C, 4 Ag/mL for 16 h) in incomplete
F medium. Medium was changed to complete F medium
after 24 h. Complete F medium is identical to incomplete F
but with epidermal growth factor (Sigma, St. Louis, MO)
supplement added at a final concentration of 10 ng/mL. Late
passage ERIN 59 cells were grown in complete F medium.
All cells were maintained in a 5% CO2 incubator at 37 -C.
All cells were divided every 4–5 days.
Cloning and sequence analysis of viral gene E2
The HPV 59 E2 ORF (nts 2736 through 3848) was
amplified by PCR from whole genomic DNA isolated from
early passage ERIN 59 cells using the following primers:
(Forward) 5V-AGATCTAGGAAGATGCAGACAGTGATG-
GAC-3V, (Reverse) 5V-GCGGCCGCCAACCATTACA-
CACTCATATAC-3V with the following cycling parameters;
94 -C for two min, followed by 30 cycles of 94 -C for 45 s,
55 -C for 45 s, and 72 -C for 60 s, followed by a single 72 -C
incubation for 5 min. The 1124 base pair amplimer (nts 2730
through 3854) was cloned into PCR-II-TOPO (Invitrogen
Corp., Grand Island, NY) and subjected to single pass primer
extension sequencing (ACGT, Inc., Wheeling, IL). Portions
of the sequence were independently verified by single pass
primer extension analysis (ACGT, Inc.) using internal
primers at E2 base pair position 2843 5V-TTGGAAACTG-
GTGCGTATGG-3V and at E2 base pair position 3376 5V-
GTGGATACTTGCTCGTCACT-3V.
Growth in athymic mice
Early passage ERIN 59 cells (passage 12) and late
passage ERIN 59 cells (passage 63 and passage 95) were
trypsinized, resuspended in complete F medium, washed in
PBS, then resuspended in PBS at 106 cells per 200 AL PBS.
The cell slurry was injected subcutaneously in the axillary
region of athymic mice at 200 AL/injection site, with four
injection sites for each cell passage (passages 12, 63, and
95). Injection sites were observed for tumor formation for 2
months. Similarly prepared HeLa cells were used as a
positive control. PBS alone was used as a negative control.
Colony formation in soft agar
PHKs, early passage ERIN 59 cells (passage 13) and late
passage ERIN 59 cells (passage 137) were trypsinized,
counted by trypan blue exclusion assay, and resuspended in
medium containing 0.3% melted SeaPlaque agarose (Cam-
brex Bio Science Rockland, Inc. Rockland, ME). Media
H. Spartz et al. / Virology 336 (2005) 11–2522used were Epilife for PHKs and complete F for early
passage ERIN 59 cells and late passage ERIN 59 cells.
Aliquots of 2 mL containing 5  104 cells were plated in
triplicate over a 2-mL base layer of solidified 0.6% agarose-
containing medium. Colonies per high power field were
counted by two observers following 5 days of incubation in
a humidified 5% CO2 incubator at 37 -C. Ten fields were
counted for each experimental group. Standard deviations
reflect the differences between three experimental replicates.
PCR/reverse blot strip assay and Southern blot analysis
DNAwas isolated from late passage (passage 142) ERIN
59 cells using the genomic DNA isolation from cultured
cells protocol (GerardBiotech, Oxford, OH). DNA concen-
tration was determined by spectrophotometry. The presence
of high molecular weight DNA was established by agarose
gel electrophoresis followed by staining with ethidium
bromide. PCR and reverse blot strip assay (Roche Molecular
Diagnostics, Carmel, IN) was performed as previously
described to confirm the presence of HPV 59 sequences
(Bryan et al., 2000).
For the Southern blot, 20 Ag of genomic DNA from
passage 142 ERIN 59 cells (prepared as above described)
was digested with BamHI, HindIII, or no added restriction
enzyme for 2 h at 37 -C. Digested DNA was separated by
0.8% agarose gel and alkaline transferred to nylon
membrane (Hybond-N+, Amersham Bioscience, Piscat-
away, NJ). To prepare the probe for Southern blot analysis,
the 8-kb genomic HPV 59 sequence was excised from the
pCR-XL-TOPO vector by endonuclease digestion using
BamHI, purified from an agarose gel and labeled with
[a-32P]dATP using the Random Primed Labeling Kit (Roche
Molecular Diagnostics). Labeled probe was purified with
Microspin G-50 Column (Amersham Bioscience). The
membrane was prehybridized with Expresshyb Solution
(BD Bioscience Clontech, San Jose, CA) for 2 h at 60 -C
and subsequently hybridized with labeled probe diluted in
Expresshyb solution for 2 h at 60 -C. After hybridization,
the membrane was washed with 2 SSC, 0.05% SDS at
room temperature for 30 min with several changes of the
solution and then 0.1 SSC, 0.1% SDS at 50 -C for 30 min.
The membrane was then exposed to X-ray film (X-OMAT
AR film, Kodak, Rochester, NY). For copy number
estimation, a total of 500 pg (approximately 9.6 copies per
cell), 200 pg (approximately 1.9 copies per cell), or 50 pgTable 1
Primer sets, numbers in parentheses indicate position of primers within the HPV
GAPDH 5V-GAAGGTGAAGGTCGGAGT-3V;
L1 (6612–6714) 5V-CTACTCGCAGCACCAATCTT-3
E1 (1265–1561) 5V-AGCGGCTATGGCTATTCTGA-3
E6/E7 (351–648) 5V-TGAGCTGCTGATACGCTGTT-3
E2 (3355–3527) 5V-CCAGTGACGAGCAAGTATCC-
E6 (232–367) 5V-ACACCGTATGCAGCGTGTCT-3
E7 (521–865) 5V-AGATCTGTGAAACACTGGTGT
Involucrin 5V-TCCTCCAGTCAATACCCATC-3(approximately 1.0 copies per cell) linearized HPV 59 whole
genomic DNA were applied to the agarose gel.
Limiting cycle PCR
Confluent early passage ERIN 59 cells (passage 13) and
late passage ERIN 59 cells (passage 63) were washed with
PBS. Proteinase K (Qiagen, Inc., Valencia, CA) was added
directly to the adherent cells followed by incubation at 55
-C for 30 min. DNAwas harvested using the QIAamp DNA
Mini Kit (Qiagen). PCR was performed using 1.2 Ag total
DNA using SuperTaq (Ambion, Inc., Austin, TX). Primers
used are indicated in Table 1. PCR was performed as
follows: 94 -C 5 min, followed by 32 cycles of 94 -C for 30
s, 55 -C for 30 s, and 72 -C for 45 s, followed by a single
incubation at 72 -C for 5 min. An aliquot of the PCR
reaction was removed after cycles 14, 20, 26, and 32. The
PCR products were applied to a 1.5% agarose gel and
visualized by ethidium bromide staining.
DNA in situ hybridization
Uninfected and HPV 59-infected foreskin xenografts
were grown in athymic mice as previously described (Bryan
et al., 2000). Early passage ERIN 59 cells (passage 12) and
late passage ERIN 59 cells (passage 52) were grown for 14
days in plastic tissue culture flasks in complete F medium
containing 2 mM calcium chloride. Medium was removed,
and the adherent cell mass was scraped from the flask. Cells
were fixed in zinc-formalin and embedded in paraffin. Four
micrometer sections were prepared, and one section was
stained with hematoxylin and eosin for histologic analysis.
Additional paraffin-embedded sections of cells and
foreskin xenografts were fixed by heating for 15 min at
80 -C. Sections were then deparaffinized in xylene followed
by ethanol. Sections were treated with 25 Ag/mL proteinase
K for 5 min at 37 -C followed by 3% H2O2 in methanol for
30 min. Sections were washed in PBS, dehydrated by
incubation in ethanol, and dried. For detection of HPV 59
DNA sequences, a probe was produced by PCR amplifica-
tion of the entire 8-kb genome followed by nick translation
using biotin-dCTP (Roche Molecular Diagnostics). The
HPV 59 DNA probe was added at 5 ng/AL to a DNA in situ
hybridization buffer (Dako Corp., Carpenteria, CA). Sec-
tions were covered with a HybriSlip (Research Products
International, Mount Prospect, IL) and heated at 95 -C for59 genome
5V-GAAGATGGTGATGGGATTTC-3V
V; 5V-TCCTCCACATGTCTGGCATA-3V
V; 5V-CCAATCGCTACAGGTAGTTC-3V
V; 5V-GAGTCGGAGTCAGGTAATTG-3V
3V; 5V-TGACACGCTGGTAGACTGAG-3V
V; 5V-AGCGTATCAGCAGCTCATGT-3V
AAAACAATG-3V; 5V-GCGGCCGCTTACTGGTTTGCTGCACACAAA-3V
V; 5V-AGTTGCTCATCTCTCTTGACT-3V
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overnight at 37 -C. Sections were washed in 20%
formamide in 2 SSC plus 0.05% Tween-20 for 10 min
at 37 -C, followed by an additional wash in 2 SSC plus
0.05% Tween-20 for 10 min at 37 -C. Sections were
blocked and probes were detected using the Tyramide
Signal Amplification Cyanine 3 System as instructed by the
manufacturer (PerkinElmer Inc., Shelton, CT). Sections
were dehydrated in ethanol and mounted using Vectashield
(Vector Laboratories, Burlingame, CA). Slides were viewed
using a fluorescent microscope at 590 nm wavelength.
Amplification of papillomavirus oncogene transcript
(APOT)
Total RNAwas harvested from late passage ERIN 59 cells
(passage 72) using RNAaqueous-4PCR (Ambion, Inc.).
Total RNA (875 ng) was reverse transcribed with an oligo
(dT)17-primer coupled to a linker sequence [(dT)17-p3, 5V-
GACAGACGCTACCACATCACTTTTTTTTTTTTTT-
TTT-3V] using the RETROscript Kit One-Step RT-PCR
(Ambion) for 20 min at 42 -C in a final volume of 25 AL.
To control for RNA and cDNA quality, PCR reactions using
GAPDH specific primers were performed as a control. First
strand cDNA containing viral oncogene sequences were then
amplified by PCR using the primers: HPV 59 E7-specific
oligonucleotide p1-59 (5V-CTGACTCCGACTCCGAGAAT-
3V) as the forward primer and p3 (5V-GACAGACGCTAC-
CACATCAC-3V) as the reverse primer. One microliter of the
forward and reverse primer pair (10 AM/primer final
concentration) was added to the reaction following the
reverse transcription step. The reaction then underwent an
initial denaturation step of 94 -C for 2 min, followed by 30
cycles of denaturation at 94 -C for 30 s, annealing at 55 -C
for 30 s, elongation at 72 -C for two min, and a final
elongation step at 72 -C for 5 min. Five microliters of the
amplification product was used as a template for nested PCR
with forward primer p2-59+ATT (5V-CTGAACCA-
CAGCGTCACAACATT-3V) and (dT)17-p3 as reverse primer
using SuperTaq (Ambion) in a 50-AL reaction and the same
cycling parameters described above. The final PCR products
were separated by electrophoresis on 1% agarose gels and
visualized by ethidium bromide staining. Visible bands were
individually cut from the gel, then eluted using GeneClean
Turbo (Qbiogene, Carlsbad, CA). The purified amplimers
were cloned using pCRII-TOPO TA cloning kit (Invitrogen)
and subjected to single pass primer extension sequence
analysis (ACGT, Inc.).
The sequenced transcript was independently verified by
RT-PCR using total RNA from late passage ERIN 59 cells
(passage 85), using the RETROscript Kit One-Step RT-PCR
(Ambion) with the following primers: a forward primer at
HPV 59 nt 50 (just upstream from the start of the E6 ORF:
5V-ACGGCATGGCACGCTTTGA-3V, and a reverse primer
at nt 2753 within the E2 ORF: 5V-GTCCATCACTGTCTG-
CATCTTC-3V). The following cycling parameters wereused: reverse transcription at 42 -C for 20 min, 94 -C for
two min, then 32 cycles of 94 -C for 30 s, 55 -C for 30 s,
and 72 -C for 45 s. The resulting amplimer was gel purified
and subjected to single pass primer extension analysis
(ACGT, Inc.).
Limiting cycle RT-PCR—viral transcripts
Total RNA was harvested from early passage ERIN 59
cells (passage 9) and late passage ERIN 59 cells (passage
73) using RNAaqueous-4PCR (Ambion). RT-PCR was
performed using 500 ng total RNA with the RETROscript
Kit One-Step RT-PCR (Ambion). Primers used are
described in Table 1 with the following cycling param-
eters: reverse transcription at 42 -C for 20 min, 94 -C for
2 min, then 32 cycles of 94 -C for 30 s, 55 -C for 30 s,
and 72 -C for 45 s. Aliquots of RT-PCR products were
removed after cycles 14, 20, 26, and 32 and applied to a
1.5% agarose gel, then visualized with ethidium bromide
staining.
Limiting cycle RT-PCR—markers of differentiation
PHKs, early passage ERIN 59 cells (passage 12), and late
passage ERIN 59 cells (passage 100) were grown to
confluence in complete F medium containing 2 mM calcium
chloride as described above. Total RNAwas harvested 7 days
following addition of calcium chloride, using RNAaqueous-
4PCR (Ambion). RNA concentration was determined by
spectrophotometry, and RT-PCR was performed on equiv-
alent quantities of total RNA using the RETROscript Kit
One-Step RT-PCR (Ambion). Primers used are described in
Table 1 with the following cycling parameters: reverse
transcription at 42 -C for 20 min, 94 -C for 2 min, then 32
cycles of 94 -C for 30 s, 55 -C for 30 s, and 72 -C for 45 s,
followed by a single incubation at 72 -C for 5 min. Aliquots
of RT-PCR products were removed after cycles 14, 20, 26,
and 32. The RT-PCR products were applied to a 1.5% agarose
gel and visualized with ethidium bromide staining. Densi-
tometry readings of GAPDH amplimers from each sample at
cycles 14, 20, 26, and 32 were performed to verify that RNA
samples were balanced.
Morphological analysis of cells induced to differentiate
PHKs, early passage ERIN 59 cells (passage 12),
and late passage ERIN 59 cells (passage 52) were
grown as described above. After reaching confluence, 2
mM calcium chloride was added to culture medium,
and cells were grown for an additional 14 days.
Medium was removed, and the adherent cell mass
was scraped from the flask. Cells were fixed in zinc-
formalin, and paraffin-embedded tissue sections were
prepared. Four-micrometer sections were prepared, and
one section was stained with hematoxylin and eosin for
histologic analysis.
H. Spartz et al. / Virology 336 (2005) 11–2524Immunohistochemistry to detect differentiation-related
proteins
To detect involucrin (a cornified cell envelope protein)
and the HPV 59 L1 major capsid protein, PHKs, early
passage ERIN 59 cells (passage 12) and late passage ERIN
59 cells (passage 52) were grown and induced to differ-
entiate as described above. Cells were harvested and
paraffin-embedded sections were prepared as described
above. Sections were deparaffinized with xylene and
ethanol, treated with 3% H2O2 in methanol to reduce
endogenous peroxidase activity, and blocked with non-
specific rabbit serum. Sections were incubated in either a
mouse monoclonal antibody against involucrin (Novocastra,
Newcastle upon Tyne, United Kingdom) at 1:100 dilution,
or to detect the L1 major capsid protein, an anti-L1 serum
(from rabbits immunized with a bacterially expressed HPV
11 trpE-L1 fusion protein) at 1:500 dilution. Preimmune
rabbit serum was used as a control. Antibody binding was
detected using the Vectastain ABC detection system (Vector
Laboratories) to yield a purple precipitate. Slides were
examined by light microscopy.Acknowledgments
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